Metis TechBio Co., Ltd. Class H (7666)

Overview

Metis TechBio Co., Ltd. Class H is an innovative biotechnology firm dedicated to revolutionizing drug formulation and delivery through AI-empowered nanomaterial advancement. Established in 2020 and headquartered in Beijing, the company operates on the cutting edge of biotechnology by developing sophisticated materials and platforms for the accurate delivery and application of therapeutic agents on carbon-based life forms. Metis TechBio caters to a diverse clientele that includes pharmaceutical firms, biotech companies, and medical research institutions in critical markets such as China and the United States. Its distinctive core technology suite, known as NanoForge, synergizes groundbreaking lipid libraries, foundational AI models, quantum chemistry, molecular dynamics simulations, and AI-driven screenings to personalize and enhance nanomaterials and their therapeutic payloads. This dual focus on AI and nanotechnology positions Metis TechBio as a pivotal player in the healthcare and biotechnology sectors, contributing substantially to the evolution of next-generation biopharmaceutical products.

Products and Services

• NanoForge: This is the company's flagship technology suite that integrates advanced lipid libraries and utilizes AI foundational models combined with quantum chemistry to design and optimize nanomaterials. NanoForge enhances the precision and efficiency of drug formulation and delivery systems.
• AiLNP: A specialized platform for nano delivery systems that utilizes artificial intelligence for creating lipid nanoparticles. AiLNP is tailored for seamless drug delivery, ensuring that active pharmaceutical ingredients reach their targeted location while maximizing efficacy and minimizing side effects.
• AiRNA: Focused on mRNA sequence design, AiRNA empowers pharmaceutical developers to create tailored mRNA sequences essential for therapies, particularly in the realms of vaccines and genetic treatments. This platform enhances the efficiency and accuracy of mRNA constructs for various therapeutic applications.
• AiTEM: This tool is designed for the formulation of small molecules, allowing researchers and developers to create optimized therapeutic agents that can be effectively used in clinical settings. AiTEM streamlines the development process of small-molecule drugs targeting diverse health conditions.
• Therapeutic Focus Areas: Metis TechBio targets critical health concerns by offering solutions applicable in oncology, metabolic disorders, autoimmune diseases, and neurodegenerative conditions. Their products and platforms are engineered to advance the development of novel therapies that address these complex diseases.